Conflicts of interest: None of the authors have any conflicts of interest to

declare. “
“The C allele of the single nucleotide polymorphism rs12979860, located near the interleukin-28B (IL-28B) gene, has a strong impact on hepatitis C virus (HCV) treatment response, as well as on spontaneous viral clearance. In patients with chronic hepatitis C (CHC), genotype CC carriers harbour HCV genotype 3 more commonly than those with non-CC genotypes. The aim of this study was to compare the HCV genotype distributions, according to IL-28B genotype, in HIV-infected patients with CHC and those with acute hepatitis C (AHC). The rs12979860 genotype was determined by polymerase chain reaction selleck products (PCR) in two subpopulations of HIV-infected BIBF1120 patients. The first consisted of 80 German patients with AHC. The second consisted of 476 patients with CHC, belonging to one German and two Spanish cohorts. In the AHC group, 31 (81.6%) rs12979860 CC carriers were infected with HCV genotype 1 or 4 vs. 32 (76.2%) among non-CC carriers (P=0.948). In patients with CHC, among those with the CC genotype, 119 (54.6%) were infected with HCV genotype 1 or 4 and 99 (45.4%)

with genotype 2 or 3, whereas in the subset with non-CC genotypes, 200 (77.5%) harboured HCV genotype 1 or 4 and 58 (22.5%) genotype 2 or 3 (P<0.001). Among HIV-infected patients with CHC, those bearing the IL-28B genotype CC were more commonly infected with genotype 3 than subjects with non-CC genotypes, whereas in HIV-infected subjects with AHC this finding was not obtained. These results strongly suggest that the protective effect of the CC genotype against evolution to CHC is mainly

exerted in patients infected with HCV genotype 1 or 4. Interleukin-28B (IL-28B) genotype has a strong impact on both spontaneous hepatitis C virus (HCV) clearance and HCV clearance induced by treatment [1–10]. Studies focusing buy Pazopanib on single nucleotide polymorphisms (SNPs) near the IL-28B gene have shown that the C allele of the SNP rs12979860 is an important predictor of treatment response both in HCV-monoinfected [1,4,10] and coinfected patients [7–9]. Interestingly, the effect of variations in IL-28B genotype is mainly seen in carriers of HCV genotype 1 or 4, while the impact on genotype 3 carriers, if any, is minimal [5,7,8]. In several reports [4,5,7,8,10], infection with HCV genotype 3 in those with chronic hepatitis C (CHC) has been shown to be significantly more prevalent among patients with the rs12979860 CC genotype than among those with non-CC genotypes. Theoretically, there are two possible explanations for this finding. On the one hand, the rs12979860 CC genotype might exert more protection against the acquisition of infection with HCV genotype 1 or 4 than against the acquisition of infection with HCV genotype 3.